Honest Criticisms and Limitations of the RECONNECT Trial
A critical examination of the RECONNECT trial's enrollment biases, follow-up gaps, statistical caveats, and generalizability concerns for bremelanotide (Vyleesi) in HSDD.
Read clinical reviewTopic Hub
Trials Reconnect
5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
5articles
29keywords mapped
2026-05-25latest review
Explore
Trials Reconnect library
Showing 5 of 5 clinical reviews.
Inside the RECONNECT Methodology: What Most Summaries Skip
A detailed methodological breakdown of the RECONNECT trial for bremelanotide (Vyleesi) in HSDD, covering randomization, blinding, endpoint definitions, statistical approach, and interpretive pitfalls.
Read clinical reviewRECONNECT Cost, Cost-Effectiveness, and Health-Economic Implications
A deep-dive into the cost-effectiveness analyses built on RECONNECT trial data for bremelanotide (Vyleesi), covering cost-per-QALY modeling, payer-coverage reality, list vs. net price gaps, and the individual patient value calculation.
Read clinical reviewRECONNECT Extension Data and What Happened After the Trial Ended
Deep dive into the RECONNECT open-label extension for bremelanotide (Vyleesi) in HSDD: durability of effect, dropout patterns, long-term safety signals, and what 12+ months of data reveal beyond the key 24-week RCT.
Read clinical reviewRECONNECT Trial: A Plain-English Overview of What It Established
A deep-dive overview of the RECONNECT trial, the key Phase 3 study behind FDA approval of bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women.
Read clinical review